In particular, our immunohistochemical analysis indicates that, whereas EBI3 was not expressed at significant levels in all BL cases, a large fraction of tumoral cells was positive for EBI3 in ∼80% of DLBCL cases. This evidence concerns the gene EBI3 and Burkitt lymphoma.